Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (OTCQX:VREOF) has issued a statement in response to a request from the Canadian Investment Regulatory Organization (CIRO) regarding recent market activity. The company confirmed that its management is unaware of any material changes in operations that could explain the recent increase in market activity.
The company included standard forward-looking statements disclaimer, noting that future events may differ from current expectations due to various risks and uncertainties.
Vireo Growth Inc. (OTCQX: VREOF) reported strong Q2 2025 financial results, with GAAP revenue reaching $48.1 million, a 91.4% increase year-over-year. The company completed three significant merger acquisitions in Utah, Missouri, and Nevada, expanding operations to six states. Key financial metrics include Adjusted EBITDA of $13.3 million and pro forma revenue of $90.7 million.
Notably, Vireo secured a $153 million refinancing, comprising a $120 million term loan at 8.3% interest and a $33 million second lien term loan with a $50 million accordion feature. This refinancing is expected to reduce annual interest expenses by over $10 million and has strengthened the company's balance sheet with over $100 million in cash.
Vireo Growth (OTCQX: VREOF) has scheduled its second quarter 2025 financial results release for August 13, 2025, before market opening. The company will host a conference call with investors on the same day at 8:30 a.m. ET to discuss the quarterly performance.
Investors can join the call by dialing 1-800-715-9871 (US/Canada toll-free) or 1-646-307-1963 (International) with conference ID 3718174. A live webcast will be available through the company's Investor Relations website.
Vireo Growth (OTCQX:VREOF) has announced the retirement of its US$10 million convertible note that was due November 1, 2024. The company has simultaneously issued a new US$10 million convertible note on July 7, 2025, as part of a larger refinancing initiative.
The transaction is classified as a "related party transaction" under MI 61-101, as the lender is considered a related party to Vireo. However, the transaction is exempt from formal valuation and minority shareholder approval requirements since the value does not exceed 25% of Vireo's market capitalization.
Vireo Growth (OTCQX:VREOF) has successfully completed a major debt refinancing and expansion of its credit facilities. The company secured a $120 million self-syndicated first lien term loan at 8.3% interest rate and a $33 million second lien term loan with a $50 million accordion feature.
The total $153 million financing package is expected to generate over $10 million in annual interest savings and provides the company with more than $100 million in cash. The refinancing consolidates debt assumed from recent mergers and optimizes the company's capital structure. Both facilities have three-year terms and can be prepaid without penalties.
Vireo Growth Inc. (OTCQX: VREOF) has announced a strategic licensing partnership with Curio Wellness to manufacture and distribute Curio's Best Self Collection products in New York's cannabis market. The agreement enables Vireo to produce and distribute Curio's complete product portfolio, including topicals, tablets, chews, and vapes, using Vireo's existing New York infrastructure.
This capital-efficient growth strategy allows Curio to enter the New York market without significant investment, while Vireo expands its portfolio with Curio's GMP-certified, nationally recognized products. The partnership leverages Vireo's established presence in New York and Curio's reputation for quality and consistency in health and wellness cannabis products.
The companies expect to launch Curio-branded products in New York dispensaries in Q4 2025.
Vireo Growth Inc. (VREOF) has successfully closed two strategic acquisitions: WholesomeCo Cannabis, a dominant player in Utah's medical market, and the Arches proprietary technology platform for a total of $69.8 million. The deal was executed through 134.2 million Subordinate Voting Shares at $0.52 per share.
The Wholesome acquisition, valued at 4.175x its 2024 Reference EBITDA of $16 million, includes clawback provisions tied to performance milestones through December 2026. Shareholders agreed to a 33-month lock-up period. The company also expects to close pending mergers in Missouri and Nevada in Q2 2025.
FAQ
What is the current stock price of Vireo Growth (VREOF)?
What is the market cap of Vireo Growth (VREOF)?
